Targeted therapy for lung cancer is a type of treatment that uses drugs designed to attack specific genetic changes driving a tumor’s growth, rather than killing all fast-dividing cells the way chemotherapy does. These drugs interfere with particular molecules or signaling pathways that cancer cells depend on, which makes them more precise and often easier to tolerate. Most targeted therapies for lung cancer come as daily pills, and they’re used primarily in non-small cell lung cancer (NSCLC), which accounts for roughly 85% of all lung cancer cases.
How Targeted Therapy Differs From Chemotherapy
Chemotherapy works by attacking all rapidly dividing cells in the body. That includes cancer cells, but also healthy cells in your hair follicles, gut lining, and bone marrow, which is why it causes such broad side effects. Targeted therapy takes a different approach: it identifies a specific molecular feature that the cancer cells rely on to grow and blocks it. Think of it as disabling a single switch rather than shutting off power to the whole building.
This selectivity means targeted therapy typically causes fewer of the severe side effects associated with chemo, like widespread hair loss or severe immune suppression. It also means the drugs only work if your tumor actually carries the specific genetic change the drug is designed to block. Not every lung cancer patient qualifies. Biomarker testing is the essential first step.
Biomarker Testing: Finding the Right Target
Before you can receive targeted therapy, your tumor needs to be tested for genetic mutations and rearrangements that drugs can act on. This is called biomarker testing or molecular profiling, and it’s done using next-generation sequencing (NGS), a technology that scans your tumor’s DNA for dozens of known changes at once.
There are two main ways to get this testing done. Tissue biopsy, where a sample of the tumor itself is analyzed, is considered the gold standard. In a study comparing both approaches in 100 patients with lung adenocarcinoma, tissue-based sequencing detected 52 therapeutic targets with a sensitivity of about 95%, while the blood-based test caught roughly 53% of the same targets. The blood-based approach, called a liquid biopsy, analyzes fragments of tumor DNA circulating in your bloodstream. It’s less invasive and useful when a tissue sample isn’t available, but a negative liquid biopsy result should generally be followed up with tissue testing to make sure nothing was missed.
The mutations and rearrangements that testing looks for include changes in EGFR, ALK, ROS1, BRAF, RET, KRAS, MET, HER2, and others. Each one has a corresponding drug or drug combination that targets it.
The Major Targets and Their Treatments
EGFR Mutations
EGFR is the most common actionable target in NSCLC. These mutations cause a protein on the cell surface to send constant “grow” signals. Drugs that block this protein are called EGFR inhibitors, and they now span three generations. First-generation drugs like gefitinib and erlotinib bind reversibly to the protein. Second-generation drugs like afatinib and dacomitinib bind permanently. The third-generation drug osimertinib is highly selective and has become a preferred first-line option in many cases, taken as a single daily pill at 80 mg. Newer third-generation options approved internationally include aumolertinib, furmonertinib, and lazertinib, all of which have shown improved outcomes compared to earlier drugs in clinical trials.
ALK and ROS1 Rearrangements
ALK rearrangements occur when part of the ALK gene fuses with another gene, producing an abnormal protein that drives cancer growth. Several drugs target this change, with crizotinib being among the first approved in 2011. It’s taken as a pill twice daily. ROS1 rearrangements work through a similar mechanism, and crizotinib was also the first drug approved for that target in 2016.
Other Actionable Targets
BRAF V600E mutations are treated with a combination of two drugs that block different points in the same growth signaling chain. RET fusions have their own class of inhibitors. HER2 mutations, once considered difficult to treat, now have approved options as well. In February 2026, the FDA granted accelerated approval to zongertinib specifically for NSCLC tumors with HER2 activating mutations, expanding the list of treatable targets further. KRAS mutations, particularly the G12C variant, also have approved targeted treatments, a breakthrough for a mutation long considered “undruggable.”
What Taking Targeted Therapy Looks Like
Most lung cancer targeted therapies are oral medications, meaning you take them at home as pills or capsules on a daily schedule. Some are taken once a day, others twice. The treatment continues for as long as the drug is controlling the cancer and side effects remain manageable, which can mean months or even years for some patients.
This is a significant practical difference from traditional chemotherapy, which typically involves periodic IV infusions at an infusion center. With targeted therapy, your regular follow-up visits focus on blood work, imaging scans to check tumor response, and monitoring for side effects.
Common Side Effects
While targeted therapy is more selective than chemotherapy, it still affects some normal cells. The cells most commonly impacted include those in the skin, nails, hair follicles, mouth, digestive tract, and bone marrow. Some targeted drugs can also affect the heart, lungs, kidneys, or thyroid over time.
Skin-related side effects are especially common with EGFR inhibitors. You might notice a rash, dry or flaking skin, redness, or changes to your nails. Diarrhea is another frequent side effect across several drug classes. These side effects are usually manageable with dose adjustments or supportive care, and your treatment team will monitor for them at regular intervals. If you develop a burning sensation, significant rash, or cracked skin, those are worth flagging to your care team promptly.
Liver enzyme changes can also occur, which is why routine blood tests are part of ongoing monitoring. In some cases, doses are reduced for patients with liver or kidney impairment to keep drug levels safe.
Why Targeted Therapy Eventually Stops Working
One of the most important things to understand about targeted therapy is that resistance almost always develops eventually. The cancer finds a way to grow despite the drug, typically within one to three years, though timelines vary widely.
Resistance falls into two categories. Primary resistance means the tumor never responds to the drug in the first place, sometimes because it carries additional genetic changes that interfere with the drug’s effect. Acquired resistance develops after an initial period of successful treatment.
Acquired resistance can happen in several ways. Sometimes the tumor develops a new mutation right at the spot where the drug binds, physically blocking it from attaching. For patients on first-generation EGFR drugs like gefitinib or erlotinib, this happens in 50 to 60% of cases through a specific secondary mutation called T790M. The third-generation drug osimertinib was actually developed to overcome this exact resistance mechanism. But osimertinib can develop its own resistance mutation, called C797S, which appears in roughly 10 to 20% of patients whose disease progresses on that drug.
Other times, the cancer bypasses the blocked pathway entirely by amplifying alternative growth signals or by transforming into a different type of cancer cell altogether. MET amplification is the most common of these bypass mechanisms, seen in about 15% of patients who progress on osimertinib. In rare cases, the tumor can even transform from non-small cell to small cell lung cancer, which requires a completely different treatment approach.
There’s also a subtler form of resistance involving small populations of cancer cells that essentially go dormant during treatment, surviving at a slow metabolic rate while the drug kills off the majority of the tumor. These “persister” cells can eventually repopulate and drive a recurrence.
When resistance develops, your oncologist will often recommend a repeat biopsy to identify the new mechanism, which can guide the next line of treatment. In some cases, another targeted drug can overcome the resistance. In others, a switch to chemotherapy, immunotherapy, or a combination becomes the next step.